Colony-Stimulating Factors for Febrile Neutropenia during Cancer Therapy

被引:122
|
作者
Bennett, Charles L. [1 ,2 ,3 ,4 ]
Djulbegovic, Benjamin [5 ,6 ,7 ]
Norris, LeAnn B. [1 ,2 ,3 ,4 ]
Armitage, James O. [8 ]
机构
[1] Univ S Carolina, South Carolina Coll Pharm, South Carolina Ctr Econ Excellence Medicat Safety, Columbia, SC 29208 USA
[2] Univ S Carolina, South Carolina Coll Pharm, Southern Network Adverse React SONAR, Columbia, SC 29208 USA
[3] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA
[4] William Jennings Bryan Dorn Vet Affairs Med Ctr, Columbia, SC USA
[5] Univ S Florida, Morsani Coll Med, Ctr Evidence Based Med & Hlth Outcome Res, Clin & Translat Sci Inst,Dept Med, Tampa, FL USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Dept Hematol, Tampa, FL USA
[7] H Lee Moffitt Canc Ctr & Res Inst, Dept Hlth Outcomes & Behav, Tampa, FL USA
[8] Univ Nebraska, Omaha Sch Med, Omaha, NE 68182 USA
来源
NEW ENGLAND JOURNAL OF MEDICINE | 2013年 / 368卷 / 12期
关键词
ACUTE MYELOID-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; NON-HODGKIN-LYMPHOMA; CELL LUNG-CANCER; BREAST-CANCER; MYELODYSPLASTIC SYNDROME; CLINICAL-TRIALS; GROWTH-FACTORS; SOLID TUMORS; DOSE-DENSE;
D O I
10.1056/NEJMct1210890
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A 55-year-old, previously healthy woman received a diagnosis of diffuse large-B-cell lymphoma after the evaluation of an enlarged left axillary lymph node obtained on biopsy. She had been asymptomatic except for the presence of enlarged axillary lymph nodes, which she had found while bathing. She was referred to an oncologist, who performed a staging evaluation. A complete blood count and test results for liver and renal function and serum lactate dehydrogenase were normal. Positron-emission tomography and computed tomography (PET-CT) identified enlarged lymph nodes with abnormal uptake in the left axilla, mediastinum, and retroperitoneum. Results on bone marrow biopsy were normal. The patient's oncologist recommends treatment with six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab (CHOP-R) at 21-day intervals. Is the administration of prophylactic granulocyte colony-stimulating factor (G-CSF) with the first cycle of chemotherapy indicated?
引用
收藏
页码:1131 / 1139
页数:9
相关论文
共 50 条
  • [21] Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice
    Ahuva Averin
    Amanda Silvia
    Lois Lamerato
    Kathryn Richert-Boe
    Manpreet Kaur
    Devi Sundaresan
    Neel Shah
    Mark Hatfield
    Tatiana Lawrence
    Gary H. Lyman
    Derek Weycker
    Supportive Care in Cancer, 2021, 29 : 2179 - 2186
  • [22] The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials
    Wang, Li
    Baser, Onur
    Kutikova, Lucie
    Page, John H.
    Barron, Richard
    SUPPORTIVE CARE IN CANCER, 2015, 23 (11) : 3131 - 3140
  • [23] Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors
    Timmer-Bonte, Johanna N. H.
    Tjan-Heijnen, Vivianne C. G.
    ANTI-CANCER DRUGS, 2006, 17 (08) : 881 - 889
  • [24] Appropriateness of granulocyte colony-stimulating factor use in patients receiving chemotherapy by febrile neutropenia risk level
    Baig, Hassam
    Somlo, Barbara
    Eisen, Melissa
    Stryker, Scott
    Bensink, Mark
    Morrow, Phuong K.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (07) : 1576 - 1585
  • [25] Impact of granulocyte colony-stimulating factors in metastatic colorectal cancer patients
    Amadio, A.
    Burkes, R.
    Bailie, T.
    McLean, M.
    Coleman, B.
    CURRENT ONCOLOGY, 2014, 21 (01) : E52 - E61
  • [26] Health Care Use and Primary Prophylaxis with Colony-Stimulating Factors
    Sullivan, Sean D.
    Ramsey, Scott D.
    Blough, David K.
    McDermott, Cara L.
    Clarke, Lauren
    McCune, Jeannine S.
    VALUE IN HEALTH, 2011, 14 (02) : 247 - 252
  • [27] Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors
    Minisini, A
    Spazzapan, S
    Crivellari, D
    Aapro, M
    Biganzoli, L
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2005, 53 (02) : 125 - 131
  • [28] Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice?
    Klastersky, Jean
    Awada, Ahmad
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 78 (01) : 17 - 23
  • [29] Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer
    Agiro, Abiy
    Ma, Qinli
    Acheson, Anupama Kurup
    Wu, Sze-Jung
    Patt, Debra A.
    Barron, John J.
    Malin, Jennifer L.
    Rosenberg, Alan
    Schilsky, Richard L.
    Lyman, Gary H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (32) : 3872 - +
  • [30] Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients
    Carrato, Alfredo
    Paz-Ares Rodriguez, Luis
    Rodriguez Lescure, Alvaro
    Casas Fernandez de Tejerina, Ana Ma
    Rubio Garcia, Eduardo Diaz
    Perez Segura, Pedro
    Constenla Figueiras, Manuel
    Garcia Carbonero, Rocio
    Gomez Codina, Jose
    Lluch Hernandez, Ana
    Maroto Rey, Jose Pablo
    Martin Jimenez, Miguel
    Mayordomo Camara, Jose Ignacio
    Moreno Nogueira, Jose Andres
    Rueda Dominguez, Antonio
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2009, 11 (07): : 446 - 454